INDIVUMED GmbH

Indivumed Therapeutics is a biotech company focused on precision oncology. We create screening-ready novel target packages and partner with the pharmaceutical industry to develop precision cancer therapeutics.

The excellent-data approach to novel target ID

With our global network of selected partner clinics, we have created unique protocols and procedures to collect tissue of unmatched quality and variety. By systematically characterizing the tissue at a molecular level and linking it with longitudinal clinical data, we can unravel novel targets that would otherwise be undetectable.

Boosting the pharmaceutical industry’s R&D pipelines

To maximize the value of our data for pharmaceutical development, we have established a holistic target identification process. Each step in this process is designed to increase the probability of successful therapeutic development further down the pipeline and the chances of a novel drug reaching the market.

Using advanced biomathematical and bioinformatics tools to reveal hidden patterns in the data, we identify novel and disease-relevant targets – in the correct tissue and for the correct cohort. Once identified, we validate a target in proprietary 2D and 3D cellular models derived from the original patient cohort. In development partnerships we contribute IP-protected target packages, containing screening-ready targets that are set up for reproducibility within our partners’ R&D pipelines.